Literature DB >> 22743296

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

Oliver Gautschi1, Chantal Pauli, Klaus Strobel, Astrid Hirschmann, Gert Printzen, Stefan Aebi, Joachim Diebold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22743296     DOI： 10.1097/JTO.0b013e3182629903

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  53 in total

Review 1.  RET fusion gene: translation to personalized lung cancer therapy.

Authors:  Takashi Kohno; Koji Tsuta; Katsuya Tsuchihara; Takashi Nakaoku; Kiyotaka Yoh; Koichi Goto
Journal:  Cancer Sci       Date:  2013-10-01       Impact factor: 6.716

2.  An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.

Authors:  Robert J G Cardnell; Carmen Behrens; Lixia Diao; YouHong Fan; Ximing Tang; Pan Tong; John D Minna; Gordon B Mills; John V Heymach; Ignacio I Wistuba; Jing Wang; Lauren A Byers
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

3.  BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.

Authors:  Fadi El Karak; Tarek Assi; Hampig Raphael Kourie; Elie El Rassy; Ralph Chebib; Maya Ghor; Samer Tabchi
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.

Authors:  Philip E Lammers; Christine M Lovly; Leora Horn
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

Review 5.  New targetable oncogenes in non-small-cell lung cancer.

Authors:  Geoffrey R Oxnard; Adam Binder; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

Review 6.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

7.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Authors:  Luping Lin; Saurabh Asthana; Elton Chan; Sourav Bandyopadhyay; Maria M Martins; Victor Olivas; Jenny Jiacheng Yan; Luu Pham; Mingxue Michelle Wang; Gideon Bollag; David B Solit; Eric A Collisson; Charles M Rudin; Barry S Taylor; Trever G Bivona
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

8.  Further advances in genetically informed lung cancer medicine.

Authors:  Caroline Nebhan; William Pao
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

9.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

Review 10.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.